György Kéri

György Kéri

György Kéri (fotó: Kata Kollár)
Born (1950-01-11)January 11, 1950
Budapest, Hungary
Died July 20, 2016(2016-07-20) (aged 66)
Budapest
Nationality Hungarian
Fields Biochemistry, Signal transduction therapy
Institutions University of California, San Francisco
Semmelweis University
Hungarian Academy of Sciences
Vichem
Alma mater Eötvös Loránd University

György Kéri (Hungarian pronunciation: [ɟørɟ ˈkeːri], January 11, 1950 – July 20, 2016) was a Széchenyi Prize winner Hungarian biochemist, professor and Doctor of Biological Sciences (D.Sc.). His major field of research was signal transduction therapy and he participated in the development of novel drug discovery technologies and drug candidates that entered the clinical development process.[1]

Biography

He studied chemistry at the Eötvös Loránd University (Budapest), where he graduated in 1973 and received a PhD in biochemistry in 1976. He worked as a postdoctoral research fellow at the University of California, San Francisco in 1978-1979. As a visiting scientist he returned to the United States 19 times for various time periods on the bases of a National Science Foundation grant and joint research programs with University of California, San Francisco and Sugen. From the Hungarian Academy of Sciences he received Candidatus of Biological Sciences (C.Sc.) in 1982 and Doctor of Biological Sciences (D.Sc.) in 1994. In 1997 he became Dr. Med. Habil. of the Semmelweis University. He is married with Mária Kenéz, has two children (Csaba 1976 and Júlia 1980) and a granddaughter Luca 2008.

History

Research

György Kéri is an internationally recognized expert on signal transduction therapy and personalized therapy. His pioneering work focuses on the utilization of signal transduction therapy approach in the pharmaceutical research. He achieved outstanding results in the research and development of peptide hormone derivatives and kinase inhibitors as antitumor agents. He was involved in the development of a signal-inhibiting somatostatin peptide compound (TT-232), which reached Phase II clinical trials, and SU101, which reached Phase III clinical trials.

Vichem – the company he co-founded in 1999 – developed a kinase inhibitor library, and a hit finding technology called Nested Chemical Library™ technology and an allosteric library for inhibiting protein-protein interactions. He has recently developed at Vichem the DriverHit Library™ for inhibiting the signaling pathways activated by cancer driver genes or mutated tumor suppressor genes.

He also participated with German researchers in the development of a new proteomic technology (Target Fishing technology) which makes possible to identify unknown targets in the signal transduction network or the interacting enzymes of the metabolom.

Over a hundred international patents or patent applications can be linked to his name, while he is a co-author of more than 250 publications in international scientific journals and several book chapters.

Membership of scientific organizations

Editorial board memberships

Awards

Main publications

Sources

  1. ↑ Zrt., HVG Kiadó (20 July 2016). "Meghalt Kéri György Széchenyi-díjas biokémikus". hvg.hu. Retrieved 4 August 2016.
This article is issued from Wikipedia - version of the 11/16/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.